YAP Subcellular Localization and Hippo Pathway Transcriptome Analysis in Pediatric Hepatocellular Carcinoma

Pediatric hepatocellular carcinoma (HCC) is a rare tumor which is associated with an extremely high mortality rate due to lack of effective chemotherapy. Recently, the Hippo pathway and its transcriptional co-activator Yes-associated protein (YAP) have been shown to play a role in hepatocyte proliferation and development of HCC in animal models. Therefore, we sought to examine the activity of YAP and the expression of Hippo pathway components in tumor and non-neoplastic liver tissue from 7 pediatric patients with moderately differentiated HCC. None of the patients had underlying cirrhosis or viral hepatitis, which is commonly seen in adults with HCC. This highlights a major difference in the pathogenesis of HCC between children and adults. We found a statistically significant increase in YAP nuclear localization in 100% of tumors. YAP target gene (CCNE1, CTGF, Cyr61) mRNA expression was also increased in the tumors that had the most significant increase in YAP nuclear localization. Based on Ki67 co-localization studies YAP nuclear localization was not simply a marker of proliferation. Our results demonstrate a clear increase in YAP activity in moderately differentiated pediatric HCC, providing evidence that it may play an important role in tumor survival and propagation.

[1]  D. Calvisi,et al.  Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. , 2014, Gastroenterology.

[2]  James S. Davis,et al.  A review of 218 pediatric cases of hepatocellular carcinoma. , 2014, Journal of pediatric surgery.

[3]  R. Yeung,et al.  Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma , 2016, Pediatric blood & cancer.

[4]  M. Wigler,et al.  Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach , 2006, Cell.

[5]  Fair M. Vassoler,et al.  Cocaine-Induced Chromatin Remodeling Increases Brain-Derived Neurotrophic Factor Transcription in the Rat Medial Prefrontal Cortex, Which Alters the Reinforcing Efficacy of Cocaine , 2010, The Journal of Neuroscience.

[6]  G. Perilongo,et al.  Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Lanfen Chen,et al.  The Hippo signaling pathway in liver regeneration and tumorigenesis. , 2015, Acta biochimica et biophysica Sinica.

[8]  V. Vacic,et al.  Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma , 2014, Science.

[9]  Jun O. Liu,et al.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.

[10]  E. Montgomery,et al.  Expression of Yes-associated protein in common solid tumors. , 2008, Human pathology.

[11]  J. Avruch,et al.  Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development , 2010, British Journal of Cancer.

[12]  D. Perek,et al.  Liver transplantation in children with hepatocellular carcinoma Do Milan criteria apply to pediatric patients? , 2009, Pediatric transplantation.

[13]  M. Esteller,et al.  Unique genomic profile of fibrolamellar hepatocellular carcinoma. , 2015, Gastroenterology.

[14]  G. Yochum,et al.  Intersection of Hippo/YAP and Wnt/β-catenin signaling pathways. , 2013, Acta biochimica et biophysica Sinica.

[15]  M. Katoh,et al.  Function and cancer genomics of FAT family genes , 2012, International journal of oncology.

[16]  P. Czauderna Adult type vs. Childhood hepatocellular carcinoma--are they the same or different lesions? Biology, natural history, prognosis, and treatment. , 2002, Medical and pediatric oncology.

[17]  H. Karakayalı,et al.  Liver transplantation for hepatocellular carcinoma in children , 2008, Pediatric transplantation.

[18]  M. Roncalli,et al.  YAP activation is an early event and a potential therapeutic target in liver cancer development. , 2014, Journal of hepatology.

[19]  A. Pobbati,et al.  Emerging roles of TEAD transcription factors and its coactivators in cancers , 2013, Cancer biology & therapy.

[20]  H. Stein,et al.  New approach to assessing lung tumours in man. , 1986, Journal of clinical pathology.

[21]  A. Schmitt,et al.  Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP , 2012, Oncogene.

[22]  H. Schmidt,et al.  Increased brain‐derived neurotrophic factor (BDNF) expression in the ventral tegmental area during cocaine abstinence is associated with increased histone acetylation at BDNF exon I‐containing promoters , 2012, Journal of neurochemistry.

[23]  F. Camargo,et al.  Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration. , 2014, American journal of physiology. Gastrointestinal and liver physiology.

[24]  C. Gilles,et al.  Regulation of membrane-type 1 matrix metalloproteinase expression by zonula occludens-2 in human lung cancer cells , 2013, Clinical & Experimental Metastasis.

[25]  R. Jaenisch,et al.  YAP1 Increases Organ Size and Expands Undifferentiated Progenitor Cells , 2007, Current Biology.

[26]  J. Quinn,et al.  Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Feldmann,et al.  Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals , 2007, Cell.

[28]  G. G. Galli,et al.  The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. , 2014, Cancer cell.

[29]  M. Tsao,et al.  Tight junction protein zo‐2 is differentially expressed in normal pancreatic ducts compared to human pancreatic adenocarcinoma , 1999, International journal of cancer.

[30]  V. Ng,et al.  Critical review of controversial issues in the management of advanced pediatric liver tumors , 2011, Pediatric blood & cancer.

[31]  E. Hiyama,et al.  Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy , 2014, Current opinion in pediatrics.

[32]  Kevin J. Cheung,et al.  Tumor Suppressor LATS1 Is a Negative Regulator of Oncogene YAP* , 2008, Journal of Biological Chemistry.

[33]  Jeannie T. Lee,et al.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. , 2009, Cancer cell.

[34]  Jianmin Zhang,et al.  Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon , 2006, Proceedings of the National Academy of Sciences.

[35]  S. Vandenberg,et al.  The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. , 2008, Neoplasia.

[36]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[37]  Caroline H. Diep,et al.  Down-Regulation of Yes Associated Protein 1 Expression Reduces Cell Proliferation and Clonogenicity of Pancreatic Cancer Cells , 2012, PloS one.

[38]  K. Ishak,et al.  Comparison of tumor pathology with duration of survival of north american patients with hepatocellular carcinoma , 1995, Cancer.

[39]  H. Sasaki,et al.  Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling , 2008, Development.

[40]  Janet Rossant,et al.  The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway. , 2010, Developmental cell.

[41]  Frank Bergmann,et al.  Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. , 2013, Gastroenterology.

[42]  E. López-Bayghen,et al.  Zona occludens-2 inhibits cyclin D1 expression and cell proliferation and exhibits changes in localization along the cell cycle. , 2008, Molecular biology of the cell.

[43]  Stefano Monti,et al.  A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma , 2015, Molecular Cancer Research.

[44]  Gary D Bader,et al.  Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. , 2010, The Biochemical journal.

[45]  U. Apte,et al.  Deregulation of Hippo kinase signalling in Human hepatic malignancies , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[46]  K. Guan,et al.  Hippo pathway regulation of gastrointestinal tissues. , 2015, Annual review of physiology.

[47]  M. Laakso,et al.  Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers , 2015, Oncogene.

[48]  Bill Bynum,et al.  Lancet , 2015, The Lancet.